%0 Journal Article
%A Krilaviciute, Agne
%A Kaaks, Rudolf
%A Seibold, Petra
%A de Vrieze, Maxime
%A Lakes, Jale
%A Radtke, Jan Philipp
%A Kuczyk, Markus
%A Harke, Nina N
%A Debus, Jürgen
%A Fink, Christoph
%A Herkommer, Kathleen
%A Gschwend, Jürgen E
%A Meissner, Valentin H
%A Benner, Axel
%A Kristiansen, Glen
%A Hadaschik, Boris
%A Arsov, Christian
%A Schimmöller, Lars
%A Antoch, Gerald
%A Giesel, Frederik L
%A Makowski, Marcus
%A Wacker, Frank
%A Schlemmer, Heinz-Peter
%A Becker, Nikolaus
%A Albers, Peter
%T Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.
%J European urology
%V 86
%N 6
%@ 0302-2838
%C Amsterdam [u.a.]
%I Elsevier Science
%M DKFZ-2024-01039
%P 493-500
%D 2024
%Z #EA:C130#LA:C130# / 2024 Dec;86(6):493-500
%X Risk-adjusted screening for prostate cancer (PCa) aims to reduce harms by less frequent retesting, especially in men at a low risk of PCa. Definitions of low risk are based mainly on studies in men starting screening at age 55-60 yr.To identify men at age 45 yr with a low risk of PCa.A population-based, risk-adjusted PCa screening trial was conducted in Germany using baseline prostate-specific antigen (PSA) starting in young men (PROBASE).PSA measurements starting at the age of 45 yr.The incidence of PCa within 5 yr was assessed in men with screen-negative baseline PSA <1.5 ng/ml compared with those with PSA 1.5-≤3.0 ng/ml.Of 23301 men who received a first PSA test at age 45 yr, 0.79
%K Low risk (Other)
%K Prostate cancer (Other)
%K Prostate-specific antigen (Other)
%K Screening (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38749854
%R 10.1016/j.eururo.2024.04.030
%U https://inrepo02.dkfz.de/record/290221